Project Grant HT94252510713
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$634K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $633,750.00 to the Icahn School of Medicine at Mount Sinai to study the "Interplay Between Sensory Neurons and NK Cells During Breast Cancer Metastatic Dormancy." The 3-year award, running from August 1, 2025 to July 31, 2028, will support advanced biomedical research to transform healthcare for military service members, veterans, and the...
This federal Project Grant award of $2,028,000.00, awarded on April 1, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at identifying epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. The award was granted to the Icahn School of Medicine at Mount Sinai, a prominent academic medical center and research institution in New York City. Through this...
The Project Grant award of $202,800 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research conducted by the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate "Spatial Copy Number and Morphologic Alterations in Early Lung Carcinogenesis". The research project aims to transform healthcare for military service members, veterans, and the broader public by advancing the...
The federal Project Grant award of $3,300,817.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at the Icahn School of Medicine at Mount Sinai (ISMMS) to leverage personalized stem cell therapy and overcome airway reconstruction challenges. This research aims to transform healthcare for military service members, veterans, and the broader public by addressing critical health...
This federal Project Grant award of $2,542,500.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research aimed at therapeutically targeting the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse, as well as preclinical models of lung metastases. The award was granted to the Weill Medical College of Cornell University, a prestigious academic medical institution, with a performance...
This $507,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research at the Icahn School of Medicine at Mount Sinai (ISMMS) to study the role of exosomes in promoting prostate cancer metastasis and resistance to androgen deprivation therapy. The 2-year grant, awarded on June 15, 2024, will enable ISMMS to conduct innovative biomedical research with the goal of advancing understanding and treatment of...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $507,000 Project Grant to the Icahn School of Medicine at Mount Sinai. The grant, effective from Sep 1, 2025 to Aug 31, 2027, will support research to investigate tumor-intrinsic epigenetic mechanisms modulating antitumor immune responses in metastatic prostate cancer. As a leading academic medical center, the Icahn School of Medicine at Mount Sinai has a strong track record of...
The federal Project Grant award of $437,420.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the Icahn School of Medicine at Mount Sinai (ISMMS) to develop innovative personalized stem cell therapies for airway reconstruction. The award, which commenced on June 1, 2025 with a planned completion date of May 31, 2029, will enable ISMMS to leverage its expertise in precision medicine and translational...
The federal Project Grant award, valued at $176,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Sloan-Kettering Institute for Cancer Research in establishing a mouse model of myxoid/round cell liposarcoma with endogenous translocations. This research aims to transform healthcare for military service members, veterans, and the broader public by advancing biomedical research on critical health...